Haemophilus b Polysaccharide Vaccine (Systemic)
Brand Names : Haemophilus influenzae type b polysaccharide vaccine, HbPV, Hib CPS, Hib polysaccharide vaccine, PRP
Haemophilus b polysaccharide
(hem-OFF-fil-us BEE pol-i-SAK-ka-ryd) vaccine is an active immunizing agent used to prevent
infection by Haemophilus influenzae
type b (Hib) bacteria.
The vaccine works by causing your body to produce its own protection (antibodies)
against the disease.
The following information applies only to the Haemophilus b polysaccharide
Infection by Haemophilus influenzae
type b (Hib)
bacteria can cause life-threatening illnesses, such as meningitis, which affects
the brain; epiglottitis, which can cause death by suffocation; pericarditis,
which affects the heart; pneumonia, which affects the lungs; and septic arthritis,
which affects the bones and joints. Hib meningitis causes death in 5 to 10%
of children who are infected. Also, approximately 30% of children who survive
Hib meningitis are left with some type of serious permanent damage, such as
mental retardation, deafness, epilepsy, or partial blindness.
Immunization against Hib is recommended for all children 24 months up to
5 years of age (i.e., up to the 5th birthday). In addition, immunization is
recommended for children 18 to 24 months of age, especially:
Children attending day-care facilities.
Children with chronic illnesses associated with increased risk of
Hib disease. These illnesses include asplenia, sickle cell disease, antibody
deficiency syndromes, immunosuppression, and Hodgkin's disease.
Children 18 to 24 months of age who have already had Hib disease.
These children may get the disease again if they are not immunized. Children
who developed Hib disease when 24 months of age or older do not need to be
immunized, since most children in this age group will develop antibodies against
Children with human immunodeficiency virus (HIV) infection or acquired
immunodeficiency syndrome (AIDS).
Children of certain racial groups, such as American Indian and Alaskan
Eskimo. Children in these groups seem to be at increased risk of Hib disease.
Children living close together with groups of other persons. Close
living conditions increase a child's risk of being exposed to persons who
have Hib infection or who carry the bacteria.
It is recommended that children immunized when they were 18 to 24 months
of age receive a second dose of vaccine, since these children may not produce
enough antibodies to fully protect them from Hib disease. Children who were
first immunized when they were 24 months of age or older do not need to be
This vaccine is available only from your doctor or other authorized health
care professional, in the following dosage form:
Commonly used names are:
Haemophilus influenzae type b polysaccharide vaccine
Hib polysaccharide vaccine
*† Not commercially available in the U.S. and Canada.